The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

ABSTRACT:

Background

Tyrosine kinase inhibitor (TKI) therapy improves the overall survival of patients with chronic myeloid leukemia (CML). However, the risk of vascular adverse events (VAEs) in these patients is reported to be higher than that in healthy individuals, because of both CML itself and the effects of TKIs. Appropriate and effective VAE risk assessment tools for TKI treatment have long been anticipated.

Methods

Here, we investigated the usefulness of a newly developed VAE risk assessment tool, the Hisayama score, and presented data on the clinical characteristics of VAEs in Japanese patients with CML based on an analysis of a real-world, large-cohort database.

Results

Patients with CML who developed VAEs were evaluated using three VAE risk assessment tools. Forty-fo

SUBMITTER: Watanabe N 

PROVIDER: S-EPMC12275440 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature